Evidence mapPaperPMID 42259798Full record

ArticleNature communications2026

Supercharged ferritin nanocages enable universal cytosolic protein delivery.

Dingkang Liu, Hong Luo, Qingzhou Lu, Lichao Yu, Minjiang Chen, Wenbing Yao, Pan Hu, Lubin Liu, Wei Liu, Xiangdong Gao and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dingkang Liu *Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0001-9839-0526
Hong Luo *Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Qingzhou Lu *Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Lichao YuJiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Wenbing YaoJiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Pan HuDepartment of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
Lubin LiuDepartment of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
Wei LiuJiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. liuwei@cpu.edu.cn.ORCID http://orcid.org/0000-0001-9819-3178
Xiangdong GaoJiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. xdgao@cpu.edu.cn.
Jiansong JiZhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China. jjstcty@wmu.edu.cn.ORCID http://orcid.org/0000-0002-6026-3676
Jun YinJiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. junyin@cpu.edu.cn.ORCID http://orcid.org/0000-0002-1529-860X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32471509National Natural Science Foundation of China (National Science Foundation of China) 82073754National Natural Science Foundation of China (National Science Foundation of China) 82273840National Natural Science Foundation of China (National Science Foundation of China) 82304368
6 · The paper itself

Abstract

Efficient intracellular protein delivery represents an essential prerequisite for protein-based biotechnologies and therapeutics targeting intracellular components. However, this process is limited by multiple factors, including nonspecific protein binding, insufficient cellular uptake, inefficient endosomal escape, and inadequate cytosolic protein release. Here we show that by engineering fully recombinant supercharged protein nanocages, we achieve exceptionally high cellular uptake using a strategy we term 'supercharged interface engineering'. By incorporating unnatural amino acids bearing phenylboronic acid groups, we develop a representative protein nanocage, pFn + . Simply mixing pFn+ with protein cargoes forms a noncovalent complex possessing enhanced cellular uptake efficiency, robust endosomal escape capability, and excellent biocompatibility. Notably, this system successfully delivers functional gene-editing tools and therapeutic antibodies in female mouse models. These findings indicate that pFn+ represents a promising platform for enhancing the cytosolic delivery of protein cargoes. Moreover, the proposed supercharged interface engineering strategy is valuable for advancing next-generation intracellular protein delivery systems.

Indexed as

CytosolFerritinsAnimalsBoronic AcidsEndosomesFemaleHumansMiceProtein EngineeringProtein TransportRecombinant Proteinsbenzeneboronic acidBoronic AcidsFerritinsRecombinant Proteins

Identifiers

PMID42259798
PMCPMC13402336

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.